Vanguard Group Inc. Has $237.05 Million Position in Amicus Therapeutics, Inc. $FOLD

Key Points

• Vanguard Group Inc. has reduced its holdings in Amicus Therapeutics by 0.7%, selling 208,342 shares and now owning approximately 29 million shares valued at $237 million.
• Several hedge funds have increased their stakes in Amicus Therapeutics, with Allspring Global Investments growing its position by 53.7% in the first quarter.
• Analysts have mixed ratings on Amicus Therapeutics, with UBS raising its target price from $21 to $22 and Goldman Sachs lowering it from $12 to $9, resulting in a consensus rating of "Moderate Buy."

Vanguard Group Inc. lowered its stake in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD - Free Report) by 0.7% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,050,621 shares of the biopharmaceutical company's stock after selling 208,342 shares during the quarter. Vanguard Group Inc. owned about 9.43% of Amicus Therapeutics worth $237,053,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in FOLD. Allspring Global Investments Holdings LLC grew its holdings in shares of Amicus Therapeutics by 53.7% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 24,530 shares of the biopharmaceutical company's stock worth $195,000 after purchasing an additional 8,567 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in Amicus Therapeutics during the first quarter worth about $1,533,000. Rice Hall James & Associates LLC lifted its position in Amicus Therapeutics by 46.6% during the first quarter. Rice Hall James & Associates LLC now owns 2,010,104 shares of the biopharmaceutical company's stock worth $16,402,000 after purchasing an additional 639,024 shares during the period. Victory Capital Management Inc. grew its stake in Amicus Therapeutics by 47.4% during the first quarter. Victory Capital Management Inc. now owns 257,088 shares of the biopharmaceutical company's stock worth $2,098,000 after buying an additional 82,691 shares in the last quarter. Finally, Edgestream Partners L.P. bought a new position in Amicus Therapeutics in the 1st quarter valued at about $477,000.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. The Goldman Sachs Group dropped their target price on shares of Amicus Therapeutics from $12.00 to $9.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Morgan Stanley upgraded shares of Amicus Therapeutics from an "equal weight" rating to an "overweight" rating in a research report on Thursday, July 17th. Wall Street Zen upgraded Amicus Therapeutics from a "hold" rating to a "buy" rating in a research note on Saturday, August 2nd. Finally, UBS Group raised their target price on Amicus Therapeutics from $21.00 to $22.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $16.22.

Amicus Therapeutics Price Performance

Amicus Therapeutics stock traded up $0.01 during mid-day trading on Friday, reaching $7.61. The company had a trading volume of 3,924,062 shares, compared to its average volume of 4,473,011. The business has a fifty day simple moving average of $6.35 and a 200 day simple moving average of $7.18. The company has a market cap of $2.35 billion, a P/E ratio of -63.41 and a beta of 0.53. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $12.65. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92.

Amicus Therapeutics Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.